Global /United States /Healthcare /Biotechnology /TRML

Tourmaline Bio, Inc.

TRML

• NASDAQ: TRML • Delayed

47.98USD 0%

As of 13 June 2026, Tourmaline Bio, Inc. has a market cap of $1.24B USD, ranking #9508 globally and #2026 in the United States. It ranks #816 in the Healthcare sector, and #155 in the Biotechnology industry.

Global Rank

9508

Country Rank

2026

Sector Rank

816

Industry Rank

155

Key Stats

Market Cap

$1.24BUSD

Enterprise Value

$998.75MUSD

EBITDA (TTM)

-$102.41MUSD

Net Income (TTM)

-$88.47MUSD

PB Ratio

4.8

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

Sandeep Kulkarni open_in_new

Employees

Founded

2021

Website

tourmalinebio.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	0.1%	0.5%	143%	184%	137%	80%	208%	-72%

News

TRML Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	TRML Tourmaline Bio Inc ISIN: US89157D1054 Shares Out.: Shares Outstanding: 25.692M¹ Shares Float: 16.805M² TV: TradingView: NASDAQ: TRML SA: Stock Analysis: NASDAQ: TRML YF: Yahoo Finance: TRML GF: Google Finance: NASDAQ: TRML NQ: NASDAQ: TRML BA: Barron's: TRML MS: Morningstar: XNAS: TRML	47.98 USD	TV: TradingView: NASDAQ: TRML SA: Stock Analysis: NASDAQ: TRML YF: Yahoo Finance: TRML GF: Google Finance: NASDAQ: TRML NQ: NASDAQ: TRML BA: Barron's: TRML MS: Morningstar: XNAS: TRML

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Tourmaline Bio, Inc.

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company’s development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 15K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 13K%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 2K%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 2K%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 2K%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 1K%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.84B 41.39B EUR 4K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 4K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 3K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 3K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 2K%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 2K%	-	Germany

chevron_leftBack